John Daniel
Internal Medicine · Richmond, VANPI 1427007996
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.5% of the total across 356 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 15.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,324 and has fallen 86.5% since, to $178 in 2024. Among internal medicine clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 356 payments — averaging $15.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$832
- Novo Nordisk$577
- Amgen$500
- GSK$440
- AstraZeneca$332
- Pfizer$318
- plus $2K from 33 others
What the payments were for
- Food & beverage$5,30099%
- Education$801%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 55 | $832 |
| Novo Nordisk | 46 | $577 |
| Amgen(2 entities) | 37 | $500 |
| GSK | 43 | $440 |
| AstraZeneca | 11 | $332 |
| Pfizer | 27 | $318 |
| Boehringer Ingelheim | 17 | $272 |
| Abbott | 10 | $239 |
| Astellas Pharma US Inc | 11 | $220 |
| Lilly USA, LLC | 15 | $209 |
| Merck | 13 | $171 |
| Insightec,inc | 2 | $150 |
| Amarin Pharma, Inc. | 8 | $144 |
| Esperion Therapeutics, Inc. | 7 | $107 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $81 |
| Novartis | 5 | $74 |
| Gilead | 4 | $66 |
| Antares Pharma, Inc. | 4 | $64 |
| Impulse Dynamics (USA) Inc. | 2 | $55 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $52 |
| Otsuka America Pharmaceutical, Inc. | 2 | $51 |
| Irhythm Technologies, Inc. | 2 | $42 |
| Kowa Pharmaceuticals America, Inc. | 3 | $41 |
| Johnson & Johnson | 3 | $40 |
| Regeneron Healthcare Solutions, Inc. | 2 | $35 |
| Biohaven Pharmaceuticals, Inc. | 2 | $31 |
| Sanofi-aventis U.S. LLC | 2 | $30 |
| Ironwood Pharmaceuticals, Inc | 2 | $28 |
| Boston Scientific | 2 | $26 |
| Medtronic | 1 | $22 |
| Actelion Pharmaceuticals US, Inc. | 1 | $19 |
| Sanofi | 1 | $18 |
| Sunovion Pharmaceuticals Inc. | 1 | $18 |
| Shire North American Group Inc | 1 | $14 |
| Bayer | 1 | $14 |
| Edwards Lifesciences | 1 | $13 |
| Nestle Healthcare Nutrition Inc. | 1 | $13 |
| Genentech USA, Inc. | 1 | $11 |
| Mannkind Corporation | 1 | $11 |
How this compares
$5,380 in reported general payments places this provider in the 90th percentile of 2,724 internal medicine providers in Virginia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 8,798 | $2,712,391 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 8,259 | $1,762,640 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 2,144 | $656,904 |
| Boostrix TdapDiphth,pertuss(Acell),tet Vac | 2,567 | $168,480 |
| TwinrixHepatitis A And B Vaccine/Pf | 337 | $48,081 |
| HavrixHepatitis A Virus Vaccine/Pf | 120 | $12,081 |
| Gardasil 9Hpv Vaccine 9-Valent/Pf | 32 | $10,260 |
| Adacel TdapDiph,pertuss(Acell),tet Vac/Pf | 97 | $6,413 |
| Typhim ViTyphoid Vi Polysacch Vaccine | 43 | $6,383 |
| Yf-VaxYellow Fever Vaccine Live/Pf | 23 | $4,820 |
| M-M-R Ii VaccineMeasles,mumps,rubella Vacc/Pf | 30 | $3,311 |
| MenquadfiMening Vac A,c,y,w135,c-Tet/Pf | 12 | $2,194 |
| IpolPoliomyelitis Vaccine, Killed | 17 | $1,040 |
| TenivacTetanus-Diphtheria Toxoids/Pf | 15 | $842 |
| ClopidogrelClopidogrel Bisulfate | 13 | $158 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerAbrysvo | $318 | $2,712,3918,798 claims |
| GSKShingrix, Arexvy, Twinrix, Havrix | $440 | $2,479,70610,860 claims |
| MerckGardasil 9 | $171 | $10,26032 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,724 internal medicine providers in Virginia.
Other internal medicine in Richmond
- Lawrence SchwartzRichmond$205K
- Wally SmithRichmond$177K
- Andrew PoklepovicRichmond$58K
- Leroy VaughanRichmond$55K
- Rachel WallerRichmond$55K
- Syed RehmanRichmond$49K
- Rafae ShaikhRichmond$41K
- Chau VoRichmond$24K
- Richard JacksonRichmond$17K
- Minh TranRichmond$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.